Dyskeratosis congenita
MONDO:0015780Dyskeratosis congenita (DC) is a rare ectodermal dysplasia that often presents with the classic triad of nail dysplasia, skin pigmentary changes, and oral leukoplakia associated with a high risk of bone marrow failure (BMF) and cancer.
Also known as: DC, DKC, Zinsser-Engman-Cole syndrome, dyskeratosis congenita, Hoyeraal-Hreidarsson syndrome, Zinsser Cole Engman syndrome
43 clinical trials for this condition and its sub-types, 12 tagged with Dyskeratosis congenita itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Dyskeratosis congenita
-
DKC1-related disorder 0 trials · 3 incl. sub-types
1 sub-type
- Dyskeratosis congenita, X-linked 0 trials · 3 incl. sub-types Sub-types →
-
Revesz syndrome 2 trials
-
2 sub-types
-
Dyskeratosis congenita, digenic 0 trials
Most studied deeper sub-types
-
New transplant method aims to reduce complications in bone marrow failure patients
Disease control OngoingThis study tests a stem cell transplant method for people with acquired or inherited bone marrow failure. Donor stem cells are specially processed to remove certain immune cells, which may lower the risk of graft rejection and graft-versus-host disease. The goal is to see if this…
Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to make bone marrow transplants safer for kids
Disease control OngoingThis pilot study tests a fludarabine-based drug regimen to prepare children with bone marrow failure syndromes for a bone marrow transplant from a matched sibling donor. The goal is to help the donor cells successfully take root while reducing serious side effects. The study incl…
Early phase 1 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New transplant approach aims to cure blood failure without harming lungs or liver
Disease control OngoingThis study tests a bone marrow transplant method that avoids harsh chemotherapy and radiation for people with dyskeratosis congenita, a genetic disorder causing bone marrow failure. The goal is to fix the blood system without worsening lung or liver disease or raising cancer risk…
Phase 2 • Sponsor: Boston Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC